CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Sensex, Nifty close flat amid volatile session; CG Power locks in at upper circuit, Deepak Nitrite tumbles by five per cent

DSIJ Intelligence 0 1310 Article rating: 4.2

Ending the week, domestic benchmark indices closed flat with a positive bias on Friday, as Sensex gained by a mere 0.04 per cent or 15.12 points to settle at 38,040.57 while Nifty rose by 0.12 per cent or by 13.90 points to reach the level of 11,214.05.

Prince Pipes rises 11.74 per cent on technical collaboration with Tooling Holland

DSIJ Intelligence 0 1288 Article rating: 3.4

Prince Pipes and Fittings Limited (PPFL), one of India’s largest integrated piping solutions & multi polymer manufacturers, announced that the company has entered into a technical collaboration with Tooling Holland BV, a global leader in the international plastic injection moulding industry based in the Netherlands.

Glenmark to launch higher strength version of oral antiviral FabiFlu

DSIJ Intelligence 0 1884 Article rating: 4.8

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

Sensex, Nifty gain by nearly one per cent; Tata Communication locks in at upper circuit, Bata declines by over four per cent

DSIJ Intelligence 0 1263 Article rating: 5.0

On Thursday, with RBI's announcement of keeping the repo rate unchanged at four per cent, Sensex rose by 362.12 points or by 0.96 per cent to close at 38,025.45 while its NSE counterpart Nifty gained by 98.50 points or 0.89 per cent to end at 11,200.15.

Lupin receives USFDA approval for Mycophenolate Mofetil tablets

DSIJ Intelligence 0 1489 Article rating: 2.4

Lupin Limited announced on Thursday that it has received approval from United States Food and Drug Administration (USFDA) for Mycophenolate Mofetil tablets USP, 500 mg, to market a generic version of CellCept® tablets of Roche Palo Alto LLC (Roche) in alliance with Concord Biotech Limited.

Meghmani Finechem starts commercial production of Hydrogen Peroxide

Apurva Joshi 0 4063 Article rating: 3.2

Meghmani Organics Limited’s subsidiary Meghmani Finechem Ltd (MFL) has started its commercial production of Hydrogen Peroxide (H2O2) from July 30, 2020, after the successful completion of the installation of integrated Hydrogen Peroxide plant in existing Chloralkali and Derivative complex at Dahej (Gujarat).

Markets expect to have a flat opening; all eyes would be on RBI policy

DSIJ Intelligence-3 0 721 Article rating: 5.0

Indian markets are expected to the begin the session with modest gains, due to sombre cues from the Asian peers. However, how markets will end today’s session would chiefly depend on the outcome of Reserve Bank of India’s (RBI) policy meet. As the retail inflation is well above the RBI’s comfort zone, street strongly believes that there won’t be any further rate cut.

Sensex, Nifty end flat; Sun Pharma Advanced Research leaps by nearly 7 per cent, EID Parry down by nearly 4 per cent

DSIJ Intelligence 0 1291 Article rating: 5.0

Domestic benchmark indices ended the trading day in the negative territory amid a volatile trading session on Wednesday. Sensex closed down marginally by a mere 24.58 points or 0.07 per cent settling at 37,663.33 while Nifty declined by 24.85 points or 0.22 per cent to close at 11,120.10.

Lupin gets US health regulator nod for Empagliflozin tablets

DSIJ Intelligence 0 991 Article rating: 4.3

Pharma major, Lupin Limited had announced on Tuesday that it has received regulatory approval from United States Food and Drug Administration (USFDA) for its Empagliflozin tablets, 10 mg and 25 mg to market a generic version of Jardiance tablets, 10 mg, and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Sensex, Nifty shine; Future Retail zooms by over 4 per cent, Bharat Electronics up by nearly 4 per cent

DSIJ Intelligence 0 1613 Article rating: 4.7

Ending a four-day losing streak, bulls made a comeback on Tuesday as Sensex gained by 748.31 points or 2.03 per cent to close at 37,687.91 while its NSE counterpart, Nifty rose by 211.25 points or 1.94 per cent to settle at 11,102.85.

Bear hug for Sensex, Nifty; CG Power locks in at upper circuit, Aditya Birla Fashion and Retail down by nearly 3 per cent

DSIJ Intelligence 0 1770 Article rating: 4.5

The month of August has begun with strong bearish sentiments prevalent in the domestic markets as Sensex slumped by 667.29 points or 1.77 per cent to close at 36,939.60 while Nifty tanked by 173.60 points or 1.57 per cent to settle at 10,899.85.

RSS
First335336337338340342343344Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR